{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T02:02:26Z","timestamp":1775268146054,"version":"3.50.1"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,4,1]],"date-time":"2021-04-01T00:00:00Z","timestamp":1617235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1016\/j.dmpk.2020.100375","type":"journal-article","created":{"date-parts":[[2020,12,13]],"date-time":"2020-12-13T10:36:33Z","timestamp":1607855793000},"page":"100375","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Physiologically based pharmacokinetic modeling of altered tizanidine systemic exposure by CYP1A2 modulation: Impact of drug-drug interactions and cigarette consumption"],"prefix":"10.1016","volume":"37","author":[{"given":"Vamshi Krishna","family":"Jogiraju","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tycho","family":"Heimbach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuliana","family":"Toderika","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David R.","family":"Taft","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.dmpk.2020.100375_bib1","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1111\/j.1742-1241.2007.01660.x","article-title":"A\u00a0clinically relevant review of tizanidine hydrochloride dose relationships to pharmacokinetics, drug safety and effectiveness in healthy subjects and patients","volume":"62","author":"Henney","year":"2008","journal-title":"Int J Clin Pract"},{"issue":"3","key":"10.1016\/j.dmpk.2020.100375_bib2","doi-asserted-by":"crossref","first-page":"435","DOI":"10.2165\/00003495-199753030-00007","article-title":"A\u00a0review of its pharmacology, clinical efficacy and tolerability in the management of spasticity associated with cerebral and spinal disorders","volume":"53","author":"Wagstaff","year":"1997","journal-title":"Drugs"},{"key":"10.1016\/j.dmpk.2020.100375_bib3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/BF00544016","article-title":"Tizanidine - initial pharmacokinetic studies in patients with spasticity","volume":"25","author":"Heazlewood","year":"1983","journal-title":"Eur J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.dmpk.2020.100375_bib4","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1111\/j.1472-8206.1987.tb00581.x","article-title":"Pharmacokinetics of orally administered tizanidine in healthy volunteers","volume":"1","author":"Tse","year":"1987","journal-title":"Fundam Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2020.100375_bib5","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1136\/jnnp.57.11.1355","article-title":"Correlations between dose, plasma concentrations, and antispastic action of tizanidine (Sirdalud\u00ae)","volume":"57","author":"Emre","year":"1994","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.dmpk.2020.100375_bib6","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.clpt.2003.12.005","article-title":"Fluvoxamine drastically increases concentrations and effects of tizanidine: a potentially hazardous interaction","volume":"75","author":"Granfors","year":"2004","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.dmpk.2020.100375_bib7","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.clpt.2004.08.018","article-title":"Ciprofloxacin greatly increases concentrations and hypotensive effect of tizanidine by inhibiting its cytochrome P450 1A2-mediated presystemic metabolism","volume":"76","author":"Granfors","year":"2004","journal-title":"Clin Pharmacol Ther"},{"issue":"3","key":"10.1016\/j.dmpk.2020.100375_bib8","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1111\/j.1365-2125.2006.02653.x","article-title":"Rofecoxib is a potent inhibitor of cytochrome P450 1A2: studies with tizanidine and caffeine in healthy subjects","volume":"62","author":"Backman","year":"2006","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.dmpk.2020.100375_bib9","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00228-006-0127-x","article-title":"Rifampicin is only a weak inducer of CYP1A2-mediated presystemic and systemic metabolism: studies with tizanidine and caffeine","volume":"62","author":"Backman","year":"2006","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.dmpk.2020.100375_bib10","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1007\/s00228-007-0389-y","article-title":"Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine","volume":"64","author":"Backman","year":"2008","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2020.100375_bib11","series-title":"Zanaflex [package insert]","year":"1996"},{"issue":"3","key":"10.1016\/j.dmpk.2020.100375_bib12","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1046\/j.1365-2125.2003.02028.x","article-title":"Tizanidine is mainly metabolized by cytochrome P450 1A2 in\u00a0vitro","volume":"57","author":"Granfors","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2020.100375_bib13","series-title":"Inhibition of CYP1A2 mediated drug metabolism in\u00a0vitro and in humans with special emphasis on rofecoxib and other NSAIDs","author":"Karjalainen","year":"2008"},{"key":"10.1016\/j.dmpk.2020.100375_bib14","series-title":"Guidance for industry: clinical drug interaction studies \u2014 clinical drug interaction studies - cytochrome p450 enzyme- and transporter-mediated drug interactions","year":"2020"},{"issue":"4","key":"10.1016\/j.dmpk.2020.100375_bib15","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1124\/dmd.116.074450","article-title":"Application of physiologically based pharmacokinetic modeling to the understanding of bosutinib pharmacokinetics: prediction of drug-drug and drug-disease interactions","volume":"45","author":"Ono","year":"2017","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.dmpk.2020.100375_bib16","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1002\/cpt.419","article-title":"Ibrutinib dosing strategies based on interaction potential of CYP3A4 perpetrators using physiologically based pharmacokinetic modeling","volume":"100","author":"de Zwart","year":"2016","journal-title":"Clin Pharmacol Ther"},{"issue":"11","key":"10.1016\/j.dmpk.2020.100375_bib17","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1007\/s40262-016-0412-5","article-title":"Evaluation of cytochrome P450 3A4-mediated drug-drug interaction potential for cobimetinib using physiologically based pharmacokinetic modeling and simulation","volume":"55","author":"Budha","year":"2016","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.dmpk.2020.100375_bib18","series-title":"physiological-based pharmacokinetic (PBPK) modeling approach to quantifying drug-drug interactions: applications to the development of fenfluramine (ZX008) for treatment of seizures in dravet syndrome (DS)","article-title":"A","author":"Li Zhang","year":"2016"},{"key":"10.1016\/j.dmpk.2020.100375_bib19","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ejps.2014.06.021","article-title":"Physiologically based pharmacokinetic modeling for assessing the clinical drug-drug interaction of alisporivir","volume":"63","author":"Xia","year":"2014","journal-title":"Eur J Pharm Sci"},{"issue":"9","key":"10.1016\/j.dmpk.2020.100375_bib20","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1016\/j.xphs.2017.04.016","article-title":"Clinical drug-drug interaction evaluations to inform drug use and enable drug access","volume":"106","author":"Rekic","year":"2017","journal-title":"J\u00a0Pharm Sci"},{"key":"10.1016\/j.dmpk.2020.100375_bib21","series-title":"Guidance for industry: in\u00a0vitro drug interaction studies \u2014cytochrome p450 enzyme- and transporter-mediated drug interactions","year":"2020"},{"key":"10.1016\/j.dmpk.2020.100375_bib22","series-title":"Guideline on the investigation of drug interactions","year":"2013"},{"key":"10.1016\/j.dmpk.2020.100375_bib23","series-title":"Physiologically based pharmacokinetic analyses - format and content","year":"2018"},{"key":"10.1016\/j.dmpk.2020.100375_bib24","series-title":"Guideline on the reporting of physiologically based pharmacokinetic (PBPK) modelling and simulation","year":"2019"},{"issue":"3","key":"10.1016\/j.dmpk.2020.100375_bib25","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1742-7843.2005.pto_973160.x","article-title":"Assessment of CYP1A2 activity in clinical practice: why, how, and when?","volume":"97","author":"Faber","year":"2005","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"2","key":"10.1016\/j.dmpk.2020.100375_bib26","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1517\/17425250802691074","article-title":"The Simcyp\u00ae population-based ADME simulator","volume":"5","author":"Jamei","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1016\/j.dmpk.2020.100375_bib27","series-title":"Package insert","year":"2013"},{"issue":"11","key":"10.1016\/j.dmpk.2020.100375_bib28","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.3109\/00498258909043177","article-title":"Biological fate of sirdalud in animals and man","volume":"19","author":"Koch","year":"1989","journal-title":"Xenobiotica"},{"issue":"4","key":"10.1016\/j.dmpk.2020.100375_bib29","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/bdd.2510140403","article-title":"Pharmacokinetics of fluvoxamine maleate after increasing single oral doses in healthy subjects","volume":"14","author":"De Vries","year":"1993","journal-title":"Biopharm Drug Dispos"},{"issue":"5","key":"10.1016\/j.dmpk.2020.100375_bib30","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1128\/AAC.36.5.993","article-title":"Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses","volume":"36","author":"Lettieri","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"issue":"9","key":"10.1016\/j.dmpk.2020.100375_bib31","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1002\/psp4.12458","article-title":"Physiologically-based pharmacokinetic modeling approach to predict rifampin-mediated intestinal p-glycoprotein induction","volume":"8","author":"Yamazaki","year":"2019","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"6","key":"10.1016\/j.dmpk.2020.100375_bib32","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1124\/dmd.30.6.684","article-title":"The disposition and metabolism of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in human subjects","volume":"30","author":"Halpin","year":"2002","journal-title":"Drug Metab Dispos"},{"issue":"10","key":"10.1016\/j.dmpk.2020.100375_bib33","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1177\/0091270003257454","article-title":"An evaluation of the dose-dependent inhibition of CYP1A2 by rofecoxib using theophylline as a CYP1A2 probe","volume":"43","author":"Bachmann","year":"2003","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.dmpk.2020.100375_bib34","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00228-011-1189-y","article-title":"Prediction of drug clearance in a smoking population: modeling the impact of variable cigarette consumption on the induction of CYP1A2","volume":"68","author":"Plowchalk","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.dmpk.2020.100375_bib35","series-title":"National center for biotechnology information","year":"2018"},{"issue":"2","key":"10.1016\/j.dmpk.2020.100375_bib37","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/S0090-9556(24)15277-4","article-title":"A\u00a0controlled pharmacokinetic evaluation of tizanidine and baclofen at steady state","volume":"27","author":"Shellenberger","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2020.100375_bib39","series-title":"Package insert","year":"2002"},{"issue":"12","key":"10.1016\/j.dmpk.2020.100375_bib40","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1124\/dmd.106.011965","article-title":"Rofecoxib is a potent, metabolism-dependent inhibitor of CYP1A2: implications for in\u00a0vitro prediction of drug interactions","volume":"34","author":"Karjalainen","year":"2006","journal-title":"Drug Metab Dispos"},{"issue":"12","key":"10.1016\/j.dmpk.2020.100375_bib41","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1007\/s12272-017-0976-0","article-title":"Prediction of drug-drug interaction potential using physiologically based pharmacokinetic modeling","volume":"40","author":"Min","year":"2017","journal-title":"Arch Pharm Res"},{"issue":"11","key":"10.1016\/j.dmpk.2020.100375_bib42","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1124\/dmd.115.065920","article-title":"Physiologically based pharmacokinetic (PBPK) modeling and simulation approaches: a systematic review of published models, applications, and model verification","volume":"43","author":"Sager","year":"2015","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"10.1016\/j.dmpk.2020.100375_bib43","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1002\/bdd.2107","article-title":"Prediction of drug-drug interactions using physiologically-based pharmacokinetic models of CYP450 modulators included in Simcyp software","volume":"39","author":"Marsousi","year":"2018","journal-title":"Biopharm Drug Dispos"},{"issue":"1","key":"10.1016\/j.dmpk.2020.100375_bib44","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.xphs.2018.10.033","article-title":"Physiologically based pharmacokinetic modeling in regulatory science: an update from the U.S. Food and drug administration\u2019s office of clinical pharmacology","volume":"108","author":"Grimstein","year":"2019","journal-title":"J\u00a0Pharm Sci"},{"issue":"12","key":"10.1016\/j.dmpk.2020.100375_bib45","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1007\/s40262-018-0661-6","article-title":"A\u00a0physiologically-based pharmacokinetic model to describe ciprofloxacin pharmacokinetics over the entire span of life","volume":"57","author":"Schlender","year":"2018","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"10.1016\/j.dmpk.2020.100375_bib46","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1128\/AAC.36.5.993","article-title":"Pharmacokinetic profiles of ciprofloxacin after single intravenous and oral doses","volume":"36","author":"Lettieri","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.dmpk.2020.100375_bib47","series-title":"Package insert","year":"2011"},{"key":"10.1016\/j.dmpk.2020.100375_bib48","series-title":"Package insert","year":"2015"},{"issue":"6","key":"10.1016\/j.dmpk.2020.100375_bib49","doi-asserted-by":"crossref","first-page":"434","DOI":"10.2165\/00003088-199019060-00003","article-title":"Clinical pharmacokinetics of ciprofloxacin","volume":"19","author":"Vance-Bryan","year":"1990","journal-title":"Clin Pharmacokinet"},{"issue":"2","key":"10.1016\/j.dmpk.2020.100375_bib50","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1177\/1087057112463732","article-title":"Application of a substrate cocktail approach in the assessment of cytochrome P450 induction using cultured human hepatocytes","volume":"18","author":"Pelletier","year":"2013","journal-title":"J\u00a0Biomol Screen"},{"issue":"11","key":"10.1016\/j.dmpk.2020.100375_bib51","doi-asserted-by":"crossref","first-page":"2355","DOI":"10.1124\/dmd.108.020602","article-title":"Modeling, prediction, and in\u00a0vitro in\u00a0vivo correlation of CYP3A4 induction","volume":"36","author":"Shou","year":"2008","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.dmpk.2020.100375_bib52","series-title":"Exposure-response relationships\u2014study design, data analysis and final regulatory applications","year":"2003"},{"issue":"10","key":"10.1016\/j.dmpk.2020.100375_bib54","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/psp4.12343","article-title":"PBPK models for CYP3A4 and P-gp DDI prediction: a modeling network of rifampicin, itraconazole, clarithromycin, midazolam, alfentanil, and digoxin","volume":"7","author":"Hanke","year":"2018","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"issue":"25","key":"10.1016\/j.dmpk.2020.100375_bib55","doi-asserted-by":"crossref","first-page":"4939","DOI":"10.1021\/jm9810102","article-title":"Correlation of human jejunal permeability (in\u00a0vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach","volume":"41","author":"Winiwarter","year":"1998","journal-title":"J\u00a0Med Chem"}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436720304365?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1347436720304365?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T19:56:23Z","timestamp":1761162983000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436720304365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4]]},"references-count":52,"alternative-id":["S1347436720304365"],"URL":"https:\/\/doi.org\/10.1016\/j.dmpk.2020.100375","relation":{},"ISSN":["1347-4367"],"issn-type":[{"value":"1347-4367","type":"print"}],"subject":[],"published":{"date-parts":[[2021,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Physiologically based pharmacokinetic modeling of altered tizanidine systemic exposure by CYP1A2 modulation: Impact of drug-drug interactions and cigarette consumption","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Pharmacokinetics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.dmpk.2020.100375","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Japanese Society for the Study of Xenobiotics. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"100375"}}